Ipsen和Biomunex伙伴利用MAIT细胞开发新的抗癌治疗方法。 Ipsen and Biomunex partner to develop new cancer-fighting treatment using MAIT cells.

Ipsen和Biomunex已经签订了一项全球独家许可证协议,为一位在免疫昆虫学领域新的MAIT细胞参与者颁发许可证。 Ipsen and Biomunex have entered into an exclusive global licensing agreement for a novel MAIT cell engager in the field of immuno-oncology. 这一伙伴关系旨在开发一种先锋治疗方法,使MAIT细胞参与防治癌症,为病人带来新的希望。 This partnership aims to develop a pioneering treatment that engages MAIT cells to combat cancer, potentially offering new hope for patients. 协定财务条款的细节没有披露。 Details of the financial terms of the agreement were not disclosed.